Based on the specific genetic mutations, tyrosine kinase inhibitors, FLT3 inhibitors, and DNA methyltransferase inhibitors can improve survival in AML patients, especially those who are unable to receive conventional chemotherapy.18, 19, 20, 21, 22, 23. Here, FLT3 is linked to acute myeloid leukemia.